# A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

> **NCT02125435** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics of ASP2408

## Interventions

- **DRUG:** ASP2408
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02125435
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125435, "A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02125435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*